Nab-paclitaxel + Cisplatin

DRUG3 trials

Sponsors

Huazhong University of Science and Technology, Shanghai Chest Hospital, Sun Yat-sen University

Conditions

Biliary Tract CancerEsophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Unresectable Locally Advanced Esophageal Cancer

Phase 1

Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer

RecruitingNCT06173986

Shanghai Chest HospitalEsophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer

Start: 2023-01-10End: 2027-12-30Target: 50Updated: 2023-12-18

Phase 2

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Huazhong University of Science and TechnologyBiliary Tract Cancer

Start: 2019-09-01End: 2021-09-01Target: 100Updated: 2020-12-31

Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer

RecruitingNCT07751055

Sun Yat-sen UniversityEsophageal Squamous Cell Carcinoma (ESCC)

Start: 2026-08-01End: 2030-12-31Target: 51Updated: 2026-08-07

Related Papers

Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial.

2025-08-16

571. A PHASE I/II MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF INDUCTION IMMUNOCHEMOTHERAPY FOLLOWED BY CONCURRENT IMMUNO-CHEMORADIOTHERAPY IN UNRESECTABLE LA-ESCC

Diseases of the Esophagus2024-09-01